Kiromic BioPharma, Inc. Common Stock
KRBP
KRBP was delisted on the 13th of September, 2023.
0 hedge funds and large institutions have $0 invested in Kiromic BioPharma, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 5 closing their positions.
0.19% less ownership
Funds ownership: 0.19% → 0% (-0.19%)
100% less funds holding
Funds holding: 5 → 0 (-5)
100% less capital invested
Capital invested by funds: $6.13K → $0 (-$6.13K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.81K |
| 2 |
BlackRock
New York
|
-$2.2K |
| 3 |
Morgan Stanley
New York
|
-$109 |
| 4 |
Wells Fargo
San Francisco,
California
|
-$16 |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$3 |
KRBP Hedge Fund Activity: Q3 2023 in Review
0 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Kiromic BioPharma, Inc. Common Stock (KRBP) for Q3 2023, worth a combined $0 — down 100% from $6.13K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of KRBP and 0 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $3.81K sold.
- 0 institutional investors held Kiromic BioPharma, Inc. Common Stock (KRBP) as of Q3 2023, down from 5 in Q2 2023.
- Funds reported $0 of Kiromic BioPharma, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
- 0 funds opened new Kiromic BioPharma, Inc. Common Stock positions in Q3 2023 and 5 closed out, a net change of -5 holders.
- The largest Kiromic BioPharma, Inc. Common Stock seller in Q3 2023 was Tower Research Capital (TRC), an estimated $3.81K sold.
Based on aggregated 13F filings for Q3 2023.